TSH Biopharm Corporation Limited (TPEX:8432)

Taiwan · Delayed Price · Currency is TWD

51.00

-1.10 (-2.11%)

Mar 9, 2026, 1:30 PM CST

-11.92% (1Y)

Market Cap	1.96B
Revenue (ttm)	1.34B
Net Income (ttm)	139.26M
Shares Out	38.40M
EPS (ttm)	3.62
PE Ratio	14.09
Forward PE	n/a
Dividend	2.12 (4.07%)
Ex-Dividend Date	Jun 16, 2025

Volume	48,626
Average Volume	48,082
Open	52.10
Previous Close	52.10
Day's Range	50.90 - 52.10
52-Week Range	43.00 - 59.30
Beta	0.34
RSI	22.03
Earnings Date	Feb 24, 2026

About TSH Biopharm Corporation

TSH Biopharm Corporation Limited develops and markets pharmaceutical products in Taiwan. The company offers prescription medication for cardiovascular, central nervous, gastrointestinal, and others. It also provides MPap, a methylation-specific qPCR technology to detect the methylation status of CDO1 and BHLHE22 genes using cervical scraping; AlphaLiquid Detect, a hybrid capture NGS-based liquid biopsy test designed for MRD detection and surveillance in stage I-III solid tumor patients; AlphaLiquid 100, a liquid biopsy test designed for patient... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1999

Employees 76

Stock Exchange Taipei Exchange

Ticker Symbol 8432

Full Company Profile

Financial Performance

In 2025, TSH Biopharm Corporation's revenue was 1.34 billion, an increase of 19.79% compared to the previous year's 1.12 billion. Earnings were 139.26 million, an increase of 23.14%.

Financial Statements

News

There is no news available yet.